Alvespimycin (hydrochloride)

Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.

Product Specifications

CAS Number

[467214-21-7]

Product Name Alternative

17-DMAG (hydrochloride) ; KOS-1022 (hydrochloride) ; BMS 826476

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; HSP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Alvespimycin-hydrochloride.html

Purity

98.80

Solubility

DMSO : ≥ 50 mg/mL|H2O : 4.76 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC.Cl

Molecular Formula

C32H49ClN4O8

Molecular Weight

653.21

Precautions

H315, H319, H320

References & Citations

[1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49 (15) :4606-15.|[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116 (1) :45-53.|[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel) . 2016 Aug 24;8 (9) . pii: E77.